var data={"title":"Varicella zoster virus vasculopathy","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Varicella zoster virus vasculopathy</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/contributors\" class=\"contributor contributor_credentials\">Maria A Nagel, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/contributors\" class=\"contributor contributor_credentials\">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/contributors\" class=\"contributor contributor_credentials\">Jennifer Mitty, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Dec 06, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Varicella zoster virus (VZV) infection of intra- and extracranial arteries (VZV vasculopathy) may be associated with a granulomatous vasculitis characterized by vessel wall damage and transmural inflammation, with multinucleated giant cells <span class=\"nowrap\">and/or</span> epithelioid macrophages. VZV vasculopathy has previously been called granulomatous angiitis, VZV vasculitis, or post-varicella arteriopathy. </p><p>The clinical spectrum of VZV vasculopathy may include intracerebral VZV vasculopathy, giant cell arteritis, and granulomatous aortitis. A subset of patients can have specific ocular and motor findings known as herpes zoster ophthalmicus with delayed contralateral hemiparesis. Intracerebral VZV vasculopathy can occur in patients of all ages after either primary infection with VZV (varicella; chickenpox) or after viral reactivation (zoster; shingles) [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/1\" class=\"abstract_t\">1</a>]; however, other forms of VZV vasculopathy (eg, giant cell arteritis) are primarily diseases of older adults. </p><p>This topic provides an overview of intracerebral VZV vasculopathy, as well as other forms of vasculopathy associated with VZV. Topic reviews that describe other clinical manifestations and complications of chickenpox and herpes zoster are found elsewhere. (See <a href=\"topic.htm?path=epidemiology-of-varicella-zoster-virus-infection-chickenpox\" class=\"medical medical_review\">&quot;Epidemiology of varicella-zoster virus infection: Chickenpox&quot;</a> and <a href=\"topic.htm?path=treatment-of-varicella-chickenpox-infection\" class=\"medical medical_review\">&quot;Treatment of varicella (chickenpox) infection&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-of-varicella-zoster-virus-infection-herpes-zoster\" class=\"medical medical_review\">&quot;Clinical manifestations of varicella-zoster virus infection: Herpes zoster&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2947884613\"><span class=\"h1\">VIROLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Varicella zoster virus (VZV), a ubiquitous DNA virus, is one of eight known human herpesviruses. Primary infection occurs via aerosols from skin vesicles from an infected person with varicella or zoster, resulting in the characteristic disseminated rash of varicella. (See <a href=\"topic.htm?path=clinical-features-of-varicella-zoster-virus-infection-chickenpox\" class=\"medical medical_review\">&quot;Clinical features of varicella-zoster virus infection: Chickenpox&quot;</a>.)</p><p>After primary infection, VZV becomes latent within neurons in cranial nerve, dorsal root, and autonomic ganglia along the entire neuraxis [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/2-5\" class=\"abstract_t\">2-5</a>]. More than 95 percent of the adult population harbors latent VZV. A decline in virus-specific cell-mediated immunity to VZV in older and immunocompromised individuals results in virus reactivation in one or more ganglia. VZV reactivation most commonly manifests as herpes zoster (ie, shingles). (See <a href=\"topic.htm?path=clinical-manifestations-of-varicella-zoster-virus-infection-herpes-zoster\" class=\"medical medical_review\">&quot;Clinical manifestations of varicella-zoster virus infection: Herpes zoster&quot;</a> and <a href=\"topic.htm?path=epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster\" class=\"medical medical_review\">&quot;Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2730566247\"><span class=\"h1\">PATHOGENESIS OF VASCULOPATHY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Varicella zoster virus (VZV) vasculopathy is associated with productive viral infection in arteries, as evidenced by the presence of multinucleated giant cells, herpesvirus particles, VZV DNA, and VZV antigen in arteries [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/6\" class=\"abstract_t\">6</a>]. </p><p class=\"headingAnchor\" id=\"H464235702\"><span class=\"h2\">Direct infection of blood vessels by VZV</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>VZV infection of intra- and extracranial arteries is associated with a spectrum of inflammatory and noninflammatory pathological changes including thrombosis, necrosis, dissection, and aneurysm formation [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/7\" class=\"abstract_t\">7</a>]. Animal studies have identified a rich supply of afferent trigeminal and dorsal root ganglionic fibers to intracranial arteries and veins, thus providing an anatomic pathway for transaxonal spread of virus after reactivation from ganglia [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/8-10\" class=\"abstract_t\">8-10</a>]. In autopsy studies of patients who died of intracranial VZV vasculopathy, pathological and virological analyses have revealed herpes virions, VZV DNA, VZV antigen, and multinucleated giant cells within the walls of cerebral arteries (<a href=\"image.htm?imageKey=ID%2F74568\" class=\"graphic graphic_picture graphicRef74568 \">picture 1</a>) [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/6,11-18\" class=\"abstract_t\">6,11-18</a>]. </p><p class=\"headingAnchor\" id=\"H446592133\"><span class=\"h2\">Role of autoantibodies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Autoantibodies to phospholipids and coagulation proteins (during or after varicella) may play a role in the occlusion of cerebral arteries [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/19,20\" class=\"abstract_t\">19,20</a>]. One report described an adult with varicella who developed a stroke and multiple peripheral thrombotic events associated with a transient protein S deficiency and transient anticardiolipin and anti-beta 2 glycoprotein antibodies [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/21\" class=\"abstract_t\">21</a>]. The presence of lupus anticoagulant [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/22\" class=\"abstract_t\">22</a>], protein S deficiency [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/22,23\" class=\"abstract_t\">22,23</a>], and anti-protein S antibody [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/23\" class=\"abstract_t\">23</a>] in association with varicella infection has also been described.</p><p class=\"headingAnchor\" id=\"H3396222153\"><span class=\"h1\">PATHOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Very similar pathological changes are seen in intracerebral varicella zoster virus (VZV) vasculopathy, giant cell arteritis (GCA), and granulomatous aortitis, which suggests a common etiology. These changes include vessel wall damage and transmural inflammation with multinucleated giant cells <span class=\"nowrap\">and/or</span> epithelioid macrophages. A common etiology is also supported by the observation that each of the disorders is not restricted to the primary artery involved. As examples:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In addition to extensive involvement of intracerebral arteries in VZV vasculopathy, extracranial arteries may also be involved.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In GCA, primary involvement of the temporal artery is frequently accompanied by disease in large arteries such as the aorta, carotid, or subclavian arteries, as well as the smaller retinal arteries.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In granulomatous aortitis, although the major arteries affected are the aorta, carotid, and subclavian arteries, many patients also have clinical features of GCA, indicating temporal artery disease. </p><p/><p>Additional discussions of the pathogenesis of these specific conditions are presented below. (See <a href=\"#H494763822\" class=\"local\">'Other types of vasculopathy'</a> below.)</p><p class=\"headingAnchor\" id=\"H1702049186\"><span class=\"h1\">INTRACEREBRAL VZV VASCULOPATHY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Intracerebral varicella zoster virus (VZV) vasculopathy can be seen in both children and adults. Early reports described ischemic large vessel strokes, although it is now appreciated that both large and small arteries are commonly involved. An expanded spectrum of stroke associated with VZV infection is now recognized including aneurysm, subarachnoid and intracerebral hemorrhage, arterial ectasia, and possibly dissection [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/24-26\" class=\"abstract_t\">24-26</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Epidemiology</span></p><p class=\"headingAnchor\" id=\"H4074289790\"><span class=\"h3\">Children</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Varicella is an important risk factor for childhood ischemic stroke [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/27\" class=\"abstract_t\">27</a>]. Approximately 1 in 15,000 cases of varicella are associated with subsequent stroke [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/27\" class=\"abstract_t\">27</a>]; most occur within 12 months of infection [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/28\" class=\"abstract_t\">28</a>]. Furthermore, varicella precedes transient cerebral arteriopathy of childhood in 44 percent of cases [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/29\" class=\"abstract_t\">29</a>]. In a large international study of immunocompetent children with stroke, 277 (53 percent) had an arteriopathy, including 19 children (7 percent) with a history of varicella-associated stroke [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/28\" class=\"abstract_t\">28</a>]. (See <a href=\"topic.htm?path=ischemic-stroke-in-children-and-young-adults-etiology-and-clinical-features\" class=\"medical medical_review\">&quot;Ischemic stroke in children and young adults: Etiology and clinical features&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H117807219\"><span class=\"h3\">Adults</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In adults, studies have found an increased risk of stroke after herpes zoster [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/30-35\" class=\"abstract_t\">30-35</a>]. The risk of stroke is greatest in those with ophthalmic-distribution zoster, and is increased soon after zoster, especially within the first three months. However, the risk of stroke can increase for at least one year after herpes zoster [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/31\" class=\"abstract_t\">31</a>]. It is unclear if the use of antiviral therapy in patients with herpes zoster prevents stroke [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/33,34\" class=\"abstract_t\">33,34</a>]. </p><p>Central nervous system (CNS)-associated vasculopathy is more common in immunocompromised individuals [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/35,36\" class=\"abstract_t\">35,36</a>]. Among HIV-infected individuals not receiving antiretroviral therapy, CNS infection caused by VZV was detected at autopsy in 1.5 to 4.4 percent of those with documented vasculopathy and leukoencephalitis [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/14,15,37-39\" class=\"abstract_t\">14,15,37-39</a>]; most cases occurred in patients with severe CD4 cell depletion. Cases have also occurred in immunocompromised patients with leukemia, lymphoma, and in those taking immunosuppressive therapies for systemic lupus erythematosus, rheumatoid arthritis, and renal transplantation [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/40,41\" class=\"abstract_t\">40,41</a>]. </p><p>Select studies that evaluated the risk of stroke in persons with herpes zoster include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A study using medical records from the Taiwan National Health Research Institute compared 7760 adults with herpes zoster and 23,280 matched controls without herpes zoster [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/30\" class=\"abstract_t\">30</a>]. After adjusting for other cardiovascular risk factors, the adjusted hazard ratio for risk of stroke among persons 45 years or older with a history of herpes zoster was 1.31 (95% CI 1.06-1.63) compared with controls. The incidence of stroke following herpes zoster ophthalmicus was higher compared with patients who had a history of herpes zoster at other cutaneous locations (5.8 versus 1.7 percent).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An analysis of medical records from a Danish national registry evaluated the risk of stroke in persons with herpes zoster [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/31\" class=\"abstract_t\">31</a>]. Individuals were considered to have herpes zoster if they received a prescription for <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> at the doses used to treat herpes zoster. Control patients were individuals who did not receive antiviral therapy for herpes zoster. Of the 117,926 zoster patients, 4876 developed stroke during the follow-up period (4.1 percent). Compared with controls, the incidence rate ratio for stroke associated with herpes zoster was 2.3 (95% CI 1.8-2.8) within two weeks after rash, 1.2 (95% CI 1.09-1.24) from two weeks to one year after rash, and 1.05 (95% CI 1.02-1.09) after the first year. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An analysis of 106,601 cases of herpes zoster and 213,202 controls matched for age, sex, and primary care practice was performed using the United Kingdom Health Improvement Network database [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/32\" class=\"abstract_t\">32</a>]. There was a statistically significant increase in transient ischemic attacks and myocardial infarctions in patients with herpes zoster; the increased risk was greatest in zoster patients &lt;40 years of age. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The UK General Practice Research Database was used to analyze 6584 individuals from 1987 to 2012 with a first-ever diagnosis of herpes zoster associated with stroke before and after rash [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/33\" class=\"abstract_t\">33</a>]. Compared with baseline, the overall rate of strokes was significantly increased in weeks 1 to 4 post-zoster (incidence rate, 1.63; 95% CI 1.32&ndash;2.02). The increased rate of stroke extended up to six months post-zoster but diminished over time. For patients with herpes zoster ophthalmicus, the greatest increase in stroke risk was delayed until weeks 5 to 12 after initial presentation. In this analysis, the 3647 zoster patients (55 percent) who received oral antiviral therapy had a reduced risk of stroke compared with the 2937 patients with herpes zoster who did not receive antiviral therapy. However, an earlier study from Taiwan found no effect of antiviral treatment on subsequent stroke among 658 individuals with ophthalmic-distribution herpes zoster [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/34\" class=\"abstract_t\">34</a>]. </p><p/><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Clinical manifestations</span></p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h3\">Neurologic manifestations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical presentations of intracerebral VZV vasculopathy can vary widely since VZV affects both large and small arteries and can result in cerebral ischemia or hemorrhage. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In adults, the classic clinical presentation of VZV vasculopathy is ophthalmic-distribution zoster followed by acute contralateral hemiplegia, whereas in children, primary varicella is followed by onset of acute hemiplegia. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Other common clinical features of VZV vasculopathy in adults include headache, mental status changes, focal weakness or sensory loss, aphasia, ataxia, and both hemianopia or monocular visual loss [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/42,43\" class=\"abstract_t\">42,43</a>]. Some patients may present with symptoms and signs consistent with encephalitis (eg, mental status changes) followed by a focal deficit [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/6\" class=\"abstract_t\">6</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Less frequently, patients with VZV vasculopathy present with transient ischemic attacks (TIA), aneurysm, subarachnoid or cerebral hemorrhage, carotid dissection, and, rarely, peripheral arterial disease [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/1,26\" class=\"abstract_t\">1,26</a>]. </p><p/><p>VZV vasculopathy may coexist with other neurologic complications of VZV, such as meningitis, radiculitis, cranial nerve disease, and myelitis or spinal cord infarction [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/44\" class=\"abstract_t\">44</a>].</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h3\">Rash</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Approximately two-thirds of patients with VZV vasculopathy have a history of zoster or varicella rash [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/40\" class=\"abstract_t\">40</a>]. Although the rash and stroke may develop simultaneously, the average time from rash to neurologic symptoms and signs is 4.1 months [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/40\" class=\"abstract_t\">40</a>]. Thus, the absence of rash should not dissuade clinicians from pursuing a diagnostic workup for VZV in the appropriate clinical setting. (See <a href=\"#H22\" class=\"local\">'Diagnosis'</a> below.)</p><p class=\"headingAnchor\" id=\"H834882164\"><span class=\"h3\">Cerebrospinal fluid testing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cerebrospinal fluid (CSF) abnormalities are common in patients with VZV vasculopathy. A modest pleocytosis, usually fewer than 100 <span class=\"nowrap\">cells/microL,</span> predominantly mononuclear cells, is seen in approximately two-thirds of patients with VZV vasculopathy [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/40\" class=\"abstract_t\">40</a>]. Many patients also have red blood cells in their CSF. CSF protein is usually elevated while glucose is normal. Oligoclonal bands are frequently present [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/45\" class=\"abstract_t\">45</a>]. CSF studies used for diagnosis (eg, VZV antibodies and VZV DNA) are discussed below. (See <a href=\"#H22\" class=\"local\">'Diagnosis'</a> below.)</p><p class=\"headingAnchor\" id=\"H464865366\"><span class=\"h2\">Imaging</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>All patients presenting with a stroke should have imaging studies. This section will discuss findings associated with VZV vasculopathy. The relative advantages of the various imaging modalities for the diagnosis of stroke are discussed elsewhere. (See <a href=\"topic.htm?path=neuroimaging-of-acute-ischemic-stroke\" class=\"medical medical_review\">&quot;Neuroimaging of acute ischemic stroke&quot;</a> and <a href=\"topic.htm?path=overview-of-the-evaluation-of-stroke\" class=\"medical medical_review\">&quot;Overview of the evaluation of stroke&quot;</a> and <a href=\"topic.htm?path=initial-assessment-and-management-of-acute-stroke\" class=\"medical medical_review\">&quot;Initial assessment and management of acute stroke&quot;</a> and <a href=\"topic.htm?path=ischemic-stroke-in-children-evaluation-initial-management-and-prognosis\" class=\"medical medical_review\">&quot;Ischemic stroke in children: Evaluation, initial management, and prognosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h3\">Brain imaging</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>VZV vasculopathy involves both large and small arteries. Mixed large and small artery disease is generally seen more often than pure small artery disease; pure large artery disease occurs least often.</p><p>Brain imaging shows ischemic or hemorrhagic infarction in virtually all cases of VZV vasculopathy [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/40\" class=\"abstract_t\">40</a>]; most lesions are bland, and some lesions enhance. Although multifocal lesions are common, VZV vasculopathy can also produce single lesions. In early reports, a single large infarct seen in the same location as the cutaneous rash was referred to as &quot;herpes zoster ophthalmicus with contralateral hemiparesis.&quot;</p><p>Magnetic resonance imaging (MRI) typically demonstrates both superficial and deep-seated lesions in both gray and white matter and particularly at gray-white matter junctions (<a href=\"image.htm?imageKey=ID%2F51689\" class=\"graphic graphic_diagnosticimage graphicRef51689 \">image 1</a>). Gray-white matter junction lesions can also be seen in patients with other disorders (eg, metastatic carcinoma and embolic disease); however, VZV vasculopathy should be included in the differential diagnosis. (See <a href=\"#H24\" class=\"local\">'Differential diagnosis'</a> below.)</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h3\">Angiographic features</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Ischemic or hemorrhagic infarction at gray-white matter junctions should prompt consideration of vascular studies, such as magnetic resonance arteriogram (MRA), computed tomography (CT) angiography, or conventional contrast dye angiography. Typical angiographic changes produced by VZV include segmental constriction, often with poststenotic dilatation (<a href=\"image.htm?imageKey=ID%2F51689\" class=\"graphic graphic_diagnosticimage graphicRef51689 \">image 1</a>). In addition to arterial occlusion, aneurysm and hemorrhage are also seen. Some of these features can also be seen in patients with other CNS vasculitides. (See <a href=\"topic.htm?path=primary-angiitis-of-the-central-nervous-system-in-adults\" class=\"medical medical_review\">&quot;Primary angiitis of the central nervous system in adults&quot;</a>.)</p><p>Although the presence of stenosis or occlusion is helpful in diagnosing VZV vasculopathy, a negative angiogram does not exclude the diagnosis, most likely because disease in small arteries is not detected as readily as in large arteries. In a series of 30 patients whose CSF tested positive for anti-VZV IgG or VZV DNA , 23 patients underwent vascular studies (conventional angiography or MRA) and 16 (70 percent) had vascular abnormalities [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/40\" class=\"abstract_t\">40</a>]. In another report of 25 patients with a variety of infectious vasculopathies, MRI showed enhancement of the arterial wall in two patients with VZV-related disease [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/46\" class=\"abstract_t\">46</a>].</p><p class=\"headingAnchor\" id=\"H22\"><span class=\"h2\">Diagnosis</span></p><p class=\"headingAnchor\" id=\"H1367719343\"><span class=\"h3\">When to suspect VZV</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>VZV vasculopathy should be suspected in a patient with a recent history of herpes zoster or varicella who presents with a transient ischemic attack, stroke, or altered mental status. VZV vasculopathy should also be considered in patients with a stroke of unknown origin [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/47\" class=\"abstract_t\">47</a>], particularly among immunocompromised and HIV-infected patients. Data that support a diagnosis of VZV vasculopathy include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A mononuclear pleocytosis in CSF. (See <a href=\"#H834882164\" class=\"local\">'Cerebrospinal fluid testing'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>MRI findings consistent with an ischemic or hemorrhagic lesion, particularly at gray-white matter junctions. Suspicion for VZV vasculopathy as the etiology of stroke is increased in the setting of multifocal <span class=\"nowrap\">and/or</span> bilateral strokes, particularly when they accrue over days to weeks. (See <a href=\"#H19\" class=\"local\">'Brain imaging'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Focal narrowing and beading in cerebral vessels on angiography. (See <a href=\"#H20\" class=\"local\">'Angiographic features'</a> above.)</p><p/><p>Since both zoster and stroke occur mostly in people over age 60, clinicians might not consider VZV vasculopathy as a cause of transient ischemic attacks or stroke months after presenting with herpes zoster. However, the average time from rash to neurologic symptoms and signs is four months. (See <a href=\"#H16\" class=\"local\">'Rash'</a> above.)</p><p class=\"headingAnchor\" id=\"H23\"><span class=\"h3\">Laboratory testing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Specific diagnostic testing should be pursued for patients with suspected VZV vasculopathy. A confirmatory laboratory diagnosis is made by demonstrating either the intrathecal production of anti-VZV antibodies or the presence of VZV DNA in CSF using a quantitative polymerase chain reaction (PCR) assay: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Quantification of virus-specific IgG in the CSF is frequently performed by calculation of a virus-specific antibody index [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/48\" class=\"abstract_t\">48</a>]. The presence of intrathecal antibodies and a reduced <span class=\"nowrap\">serum/CSF</span> ratio confirms the diagnosis. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>PCR assays use primers specific for VZV, sensitive enough to detect approximately 100 copies of viral DNA.</p><p/><p>Only negative results in both anti-VZV IgG antibody testing and VZV PCR in the CSF would exclude the diagnosis of VZV vasculopathy [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/49\" class=\"abstract_t\">49</a>].</p><p>Testing for anti-VZV IgG antibody in the CSF generally has a higher yield than testing for VZV DNA. Anti-VZV IgG antibody becomes detectable during the second week after infection [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/40\" class=\"abstract_t\">40</a>], whereas VZV DNA may only be present during the first two weeks of infection. This is important since VZV vasculopathy is often unsuspected, and testing may be performed late in the clinical course. However, the yield of VZV DNA testing may be higher in immunocompromised hosts.</p><p>The specificity of the enzyme immunoassay test used for detection of VZV antibody appears robust. When this test was performed on more than 1600 CSF samples from subjects with migraine, epilepsy, and other CNS encephalitides (eg, herpes simplex virus, Epstein-Barr virus, West Nile virus), no patient had detectable anti-VZV IgG antibody [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/49\" class=\"abstract_t\">49</a>].</p><p>The use of antibody testing was supported in a study of patients from multiple institutions in the United States, Europe, and Japan with virologically verified VZV vasculopathy [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/40\" class=\"abstract_t\">40</a>]. In this series, 28 of 30 (93 percent) patients with VZV vasculopathy had anti-VZV IgG in the CSF compared with only 30 percent with VZV DNA in CSF; in each of the patients with detectable anti-VZV IgG in CSF, a reduced <span class=\"nowrap\">serum/CSF</span> ratio of VZV IgG confirmed intrathecal synthesis.</p><p class=\"headingAnchor\" id=\"H24\"><span class=\"h2\">Differential diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>VZV is the only human virus that has been shown to replicate in arteries and produce vasculopathy [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/1\" class=\"abstract_t\">1</a>]. However, many of the same symptoms, signs, CSF abnormalities (eg, pleocytosis), imaging, and arteriographic abnormalities that occur in VZV vasculopathy are seen in other CNS disorders, such as primary angiitis of the nervous system and granulomatous angiitides of the CNS (eg, sarcoidosis, neurosyphilis, and tuberculous and fungal infections). (See <a href=\"topic.htm?path=primary-angiitis-of-the-central-nervous-system-in-adults\" class=\"medical medical_review\">&quot;Primary angiitis of the central nervous system in adults&quot;</a> and <a href=\"topic.htm?path=extrapulmonary-manifestations-of-sarcoidosis#H18586425\" class=\"medical medical_review\">&quot;Extrapulmonary manifestations of sarcoidosis&quot;, section on 'Neurologic'</a> and <a href=\"topic.htm?path=neurosyphilis#H10\" class=\"medical medical_review\">&quot;Neurosyphilis&quot;, section on 'Meningovascular syphilis'</a>.)</p><p>In addition, hypercoagulable states, multifocal cardiac embolism, and intravascular lymphoma can produce a pattern of multifocal stroke similar to that seen in vasculitis. (See <a href=\"topic.htm?path=ischemic-stroke-in-children-and-young-adults-etiology-and-clinical-features#H12\" class=\"medical medical_review\">&quot;Ischemic stroke in children and young adults: Etiology and clinical features&quot;, section on 'Vasculitis'</a>.)</p><p class=\"headingAnchor\" id=\"H25\"><span class=\"h2\">Treatment</span></p><p class=\"headingAnchor\" id=\"H3386040829\"><span class=\"h3\">Initial regimen</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are no controlled trials to assess the optimal treatment strategy for patients with intracerebral VZV vasculopathy. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with suspected intracerebral VZV vasculopathy, we suggest empiric intravenous <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> (10 <span class=\"nowrap\">mg/kg</span> intravenously [IV] every eight hours) while awaiting CSF testing for anti-VZV IgG antibody or VZV DNA. (See <a href=\"#H22\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with a confirmed diagnosis of VZV vasculopathy: </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>We administer IV <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> for 14 days. The duration may need to be extended for those who do not respond to initial treatment. (See <a href=\"#H26\" class=\"local\">'Monitoring response to treatment'</a> below and <a href=\"#H2772046922\" class=\"local\">'Patients who do not respond to initial treatment'</a> below.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>We also suggest a short course of oral <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> (1 <span class=\"nowrap\">mg/kg</span> daily for five days) without a steroid taper [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/7\" class=\"abstract_t\">7</a>]. It is not known if glucocorticoids confer additional benefit to antiviral agents; however, we give a short course of prednisone to minimize the inflammatory response in VZV-infected arteries.</p><p/><p>Prompt treatment in suspected cases of VZV vasculopathy may be important to improve treatment outcomes. In the case series of 30 patients described above, individuals were treated with antiviral therapy, steroids, or both [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/40\" class=\"abstract_t\">40</a>]; improvement or stabilization of neurologic deficits was seen in 75 percent of those treated with both <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> and steroids and in 66 percent of those treated with acyclovir alone.</p><p class=\"headingAnchor\" id=\"H26\"><span class=\"h3\">Monitoring response to treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>During intravenous antiviral therapy, the patient should be monitored clinically to assess if the neurological deficits have stabilized and if any new strokes have occurred. </p><p>Based upon our clinical experience, we suggest a repeat CSF analysis if:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The patient is not responding clinically within two weeks of intravenous antiviral therapy. This includes patients who have not returned to baseline, especially if they had an initial CSF that contained more than 50 white blood <span class=\"nowrap\">cells/microL</span>. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Progression of neurologic symptoms associated with new lesions on a repeat MRI. If the patient is stable or improving there is no need for a repeat MRI.</p><p/><p>A repeat CSF analysis should include cell count and chemistries, as well as re-evaluation for other concomitant infectious agents, such as mycobacteria, fungi, and <em>Treponema pallidum</em> (the causative agent of neurosyphilis). This is particularly important in patients with AIDS or other significant immunocompromising conditions in which multiple infections may coexist. Repeat testing for VZV is not helpful in this setting. (See <a href=\"#H24\" class=\"local\">'Differential diagnosis'</a> above.) </p><p class=\"headingAnchor\" id=\"H2772046922\"><span class=\"h3\">Patients who do not respond to initial treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Initially, we treat patients for a minimum of 14 days with antiviral therapy. (See <a href=\"#H3386040829\" class=\"local\">'Initial regimen'</a> above.)</p><p/><p>We typically extend the duration of intravenous <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> for an additional two to four weeks if the patient does not improve clinically, develops new lesions by MRI, or has a persistent pleocytosis after two weeks. Unlike most acute viral encephalitides, VZV vasculopathy is often chronic and protracted. We have encountered multiple patients with VZV vasculopathy who continue to have new neurologic symptoms such as focal weakness and altered mental status after intravenous acyclovir treatment; most of these patients were HIV infected.</p><p class=\"headingAnchor\" id=\"H494763822\"><span class=\"h1\">OTHER TYPES OF VASCULOPATHY</span></p><p class=\"headingAnchor\" id=\"H3647602221\"><span class=\"h2\">VZV vasculopathy with temporal artery infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Varicella zoster virus (VZV) may be associated with a multifocal vasculopathy that presents with the clinical and laboratory features of giant cell arteritis (GCA) and temporal artery infection (<a href=\"image.htm?imageKey=RHEUM%2F54634\" class=\"graphic graphic_table graphicRef54634 \">table 1</a>). As with other types of VZV vasculopathy, a history of a zoster rash is not always present [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/50,51\" class=\"abstract_t\">50,51</a>]. A more detailed discussion of the clinical manifestations of GCA are presented elsewhere. (See <a href=\"topic.htm?path=clinical-manifestations-of-giant-cell-temporal-arteritis\" class=\"medical medical_review\">&quot;Clinical manifestations of giant cell (temporal) arteritis&quot;</a>.)</p><p>Patients with VZV vasculopathy and temporal artery infection may develop visual loss associated with VZV infection of the ophthalmic <span class=\"nowrap\">and/or</span> retinal arteries. Due to the multifocal nature of VZV vasculopathy and the rich innervation of the vascular supply to the optic nerve and retina, VZV vasculopathy may produce a spectrum of ischemic injuries such as anterior and posterior ischemic optic neuropathy (ION), retinal necrosis, and central retinal artery occlusion [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/50,52\" class=\"abstract_t\">50,52</a>]. </p><p>When extensive serial sections of temporal artery biopsies are examined, virtually identical pathological changes are seen in the arteries of patients with intracerebral VZV vasculopathy and VZV vasculopathy associated with temporal artery infection. The pathology is characterized by granulomatous vasculitis, in which inflammation, often transmural, is seen with necrosis, usually in the arterial media, accompanied by multinucleated giant cells, epithelioid macrophages, or both. (See <a href=\"#H2730566247\" class=\"local\">'Pathogenesis of vasculopathy'</a> above.) </p><p>In addition, virological analysis of temporal arteries have shown that VZV is present in most GCA-positive and GCA-negative temporal artery biopsies, mostly in skip areas that correlate with adjacent GCA pathology [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/50,52-56\" class=\"abstract_t\">50,52-56</a>]. The prevalence of VZV in the temporal arteries of patients with clinically suspected GCA is similar, independent of whether biopsy is negative or positive pathologically [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/52,57\" class=\"abstract_t\">52,57</a>].</p><p>A retrospective analysis evaluated archived formalin-fixed, paraffin-embedded GCA-positive and GCA-negative temporal artery biopsies (50 <span class=\"nowrap\">sections/temporal</span> artery) from subjects &gt;50 years across 13 centers in the United States, Canada, Iceland, France, Germany, and Israel, who were reported to have clinical manifestations and laboratory features of GCA [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/56\" class=\"abstract_t\">56</a>]. Immunohistochemical analyses showed VZV antigen in 73 of 104 (70 percent) of GCA-positive and 58 of 100 (58 percent) of GCA-negative temporal arteries, compared with 11 of 61 (18 percent) of arteries that were removed postmortem from age-matched controls. Overall, VZV antigen was 3.89-fold more likely to be present in GCA-positive temporal arteries than normal temporal arteries (95% CI 2.38-7.24), and 3.22 times more likely to be present in GCA-negative than normal temporal arteries (95% CI 1.94-6.03). In addition, GCA-negative temporal artery biopsies were found to contain VZV antigen in five of seven (71 percent) patients with anterior ischemic optic neuropathy (AION). VZV DNA was readily detected in 18 of 45 (40 percent) of <span class=\"nowrap\">GCA-positive/VZV</span> antigen-positive temporal arteries; 6 of 10 (60 percent) VZV antigen-positive skeletal muscles; and 1 VZV antigen-positive normal temporal artery, despite formalin fixation. </p><p>Despite the association of VZV infection and GCA described above, some experts feel direct pathogenetic evidence of a causal role for VZV in GCA is still insufficient. (See <a href=\"topic.htm?path=pathogenesis-of-giant-cell-arteritis\" class=\"medical medical_review\">&quot;Pathogenesis of giant cell arteritis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3140366128\"><span class=\"h2\">VZV-associated granulomatous aortitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>VZV may be associated with granulomatous aortitis. Granulomatous aortitis should be suspected in patients with back or abdominal pain, as well as symptoms and signs of aortic insufficiency, particularly if patients also have features consistent with GCA. Other common complaints included shortness of breath, chest pain, diplopia, weight loss, nausea, and fatigue. One study detected VZV infection in the aortas of 11 patients with granulomatous aortitis; most subjects had aortic aneurysm (some with aortic stenosis or dilatation) and coronary artery disease [<a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/58\" class=\"abstract_t\">58</a>]. </p><p>Conventional angiography may show luminal abnormalities, but computed tomography angiography (CTA) and magnetic resonance angiography (MRA) are preferred since they can show stenosis, dilatation, and inflammation of the aortic wall. Abdominal ultrasonography may show thickening of the vessel wall and a halo sign reflective of inflammation. Other testing used in the diagnosis of vasculitis, such as the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) may be elevated in patients with granulomatous aortitis, but these findings are nonspecific. (See <a href=\"topic.htm?path=overview-of-and-approach-to-the-vasculitides-in-adults#H21\" class=\"medical medical_review\">&quot;Overview of and approach to the vasculitides in adults&quot;, section on 'Diagnostic approach'</a>.)</p><p class=\"headingAnchor\" id=\"H4159240775\"><span class=\"h2\">Management considerations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are no controlled trials evaluating the use of antiviral therapy for the treatment of VZV-associated temporal artery infection or granulomatous aortitis. Although some experts endorse antiviral therapy since the risk of treatment is low, most providers do not routinely administer antiviral therapy to such patients. (See <a href=\"topic.htm?path=treatment-of-giant-cell-arteritis\" class=\"medical medical_review\">&quot;Treatment of giant cell arteritis&quot;</a> and <a href=\"topic.htm?path=overview-of-the-management-of-vasculitis-in-adults\" class=\"medical medical_review\">&quot;Overview of the management of vasculitis in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1911800653\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-varicella-zoster-virus\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Varicella-zoster virus&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H29\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Varicella zoster virus (VZV), a ubiquitous DNA virus, is one of eight known human herpesviruses. After primary varicella infection (chickenpox), VZV becomes latent within neurons in cranial nerves, dorsal roots, and autonomic ganglia along the entire neuraxis. Herpes zoster (shingles) results from virus reactivation in one or more ganglia. (See <a href=\"#H2947884613\" class=\"local\">'Virology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>VZV is associated with vasculopathy, as evidenced by the presence of multinucleated giant cells, herpesvirus particles, VZV DNA, and VZV antigen in arteries. (See <a href=\"#H2730566247\" class=\"local\">'Pathogenesis of vasculopathy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intracerebral VZV vasculopathy can be seen in both children and adults (see <a href=\"#H1702049186\" class=\"local\">'Intracerebral VZV vasculopathy'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In adults, the classic clinical presentation of VZV vasculopathy is ophthalmic-distribution zoster followed by acute contralateral hemiplegia; whereas in children, primary varicella may be followed by onset of acute hemiplegia. The average time from rash to neurologic symptoms and signs is approximately four months. (See <a href=\"#H14\" class=\"local\">'Clinical manifestations'</a> above.) </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>VZV can affect both large and small arteries and can result in cerebral ischemia or hemorrhagic lesions, particularly at gray-white matter junctions. Suspicion for VZV vasculopathy as the etiology of stroke is increased in the setting of multifocal <span class=\"nowrap\">and/or</span> bilateral strokes, particularly when they accrue over days to weeks. (See <a href=\"#H464865366\" class=\"local\">'Imaging'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>A laboratory diagnosis of VZV vasculopathy is made by demonstrating either the intrathecal production of anti-VZV antibodies or the presence of VZV DNA in cerebrospinal fluid (CSF) using a quantitative polymerase chain reaction assay (PCR). Testing for anti-VZV IgG antibody in the CSF generally has a higher yield than testing for VZV DNA. (See <a href=\"#H22\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For patients with suspected intracerebral VZV vasculopathy, we suggest empiric intravenous <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> while awaiting their CSF laboratory test results (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). A reasonable regimen is 10 <span class=\"nowrap\">mg/kg</span> every 8 hours. (See <a href=\"#H3386040829\" class=\"local\">'Initial regimen'</a> above.) </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For patients with a confirmed diagnosis of VZV vasculopathy, we administer intravenous <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> for 14 days. For such patients, we also suggest a short course of oral <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> (1 <span class=\"nowrap\">mg/kg</span> daily for five days) without a steroid taper (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H3386040829\" class=\"local\">'Initial regimen'</a> above.) </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The course of <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> can be extended for patients who do not respond initially. (See <a href=\"#H26\" class=\"local\">'Monitoring response to treatment'</a> above and <a href=\"#H2772046922\" class=\"local\">'Patients who do not respond to initial treatment'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>VZV may be associated with a multifocal vasculopathy that presents with the clinical and laboratory features of giant cell arteritis (GCA) and temporal artery infection. It may also be associated with granulomatous aortitis. (See <a href=\"#H494763822\" class=\"local\">'Other types of vasculopathy'</a> above.) </p><p/><p><strong>ACKNOWLEDGMENT</strong>&nbsp;&mdash;&nbsp;We are saddened by the death of Donald H Gilden, MD, who passed away in August 2016. UpToDate wishes to acknowledge Dr. Gilden's many contributions to the Infectious Diseases specialty.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/1\" class=\"nounderline abstract_t\">Gilden D, Cohrs RJ, Mahalingam R, Nagel MA. Varicella zoster virus vasculopathies: diverse clinical manifestations, laboratory features, pathogenesis, and treatment. Lancet Neurol 2009; 8:731.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/2\" class=\"nounderline abstract_t\">Gilden DH, Vafai A, Shtram Y, et al. Varicella-zoster virus DNA in human sensory ganglia. Nature 1983; 306:478.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/3\" class=\"nounderline abstract_t\">Mahalingam R, Wellish M, Wolf W, et al. Latent varicella-zoster viral DNA in human trigeminal and thoracic ganglia. N Engl J Med 1990; 323:627.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/4\" class=\"nounderline abstract_t\">Nagel MA, Rempel A, Huntington J, et al. Frequency and abundance of alphaherpesvirus DNA in human thoracic sympathetic ganglia. J Virol 2014; 88:8189.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/5\" class=\"nounderline abstract_t\">Cohrs RJ, Gilden DH. Prevalence and abundance of latently transcribed varicella-zoster virus genes in human ganglia. J Virol 2007; 81:2950.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/6\" class=\"nounderline abstract_t\">Gilden DH, Kleinschmidt-DeMasters BK, Wellish M, et al. Varicella zoster virus, a cause of waxing and waning vasculitis: the New England Journal of Medicine case 5-1995 revisited. Neurology 1996; 47:1441.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/7\" class=\"nounderline abstract_t\">Kleinschmidt-DeMasters BK, Gilden DH. Varicella-Zoster virus infections of the nervous system: clinical and pathologic correlates. Arch Pathol Lab Med 2001; 125:770.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/8\" class=\"nounderline abstract_t\">Mayberg M, Langer RS, Zervas NT, Moskowitz MA. Perivascular meningeal projections from cat trigeminal ganglia: possible pathway for vascular headaches in man. Science 1981; 213:228.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/9\" class=\"nounderline abstract_t\">Mayberg MR, Zervas NT, Moskowitz MA. Trigeminal projections to supratentorial pial and dural blood vessels in cats demonstrated by horseradish peroxidase histochemistry. J Comp Neurol 1984; 223:46.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/10\" class=\"nounderline abstract_t\">Saito K, Moskowitz MA. Contributions from the upper cervical dorsal roots and trigeminal ganglia to the feline circle of Willis. Stroke 1989; 20:524.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/11\" class=\"nounderline abstract_t\">Linnemann CC Jr, Alvira MM. Pathogenesis of varicella-zoster angiitis in the CNS. Arch Neurol 1980; 37:239.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/12\" class=\"nounderline abstract_t\">Doyle PW, Gibson G, Dolman CL. Herpes zoster ophthalmicus with contralateral hemiplegia: identification of cause. Ann Neurol 1983; 14:84.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/13\" class=\"nounderline abstract_t\">Eidelberg D, Sotrel A, Horoupian DS, et al. Thrombotic cerebral vasculopathy associated with herpes zoster. Ann Neurol 1986; 19:7.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/14\" class=\"nounderline abstract_t\">Morgello S, Block GA, Price RW, Petito CK. Varicella-zoster virus leukoencephalitis and cerebral vasculopathy. Arch Pathol Lab Med 1988; 112:173.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/15\" class=\"nounderline abstract_t\">Gray F, B&eacute;lec L, Lescs MC, et al. Varicella-zoster virus infection of the central nervous system in the acquired immune deficiency syndrome. Brain 1994; 117 ( Pt 5):987.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/16\" class=\"nounderline abstract_t\">Amlie-Lefond C, Kleinschmidt-DeMasters BK, Mahalingam R, et al. The vasculopathy of varicella-zoster virus encephalitis. Ann Neurol 1995; 37:784.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/17\" class=\"nounderline abstract_t\">Melanson M, Chalk C, Georgevich L, et al. Varicella-zoster virus DNA in CSF and arteries in delayed contralateral hemiplegia: evidence for viral invasion of cerebral arteries. Neurology 1996; 47:569.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/18\" class=\"nounderline abstract_t\">Kleinschmidt-DeMasters BK, Mahalingam R, Shimek C, et al. Profound cerebrospinal fluid pleocytosis and Froin's Syndrome secondary to widespread necrotizing vasculitis in an HIV-positive patient with varicella zoster virus encephalomyelitis. J Neurol Sci 1998; 159:213.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/19\" class=\"nounderline abstract_t\">Manco-Johnson MJ, Nuss R, Key N, et al. Lupus anticoagulant and protein S deficiency in children with postvaricella purpura fulminans or thrombosis. J Pediatr 1996; 128:319.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/20\" class=\"nounderline abstract_t\">Josephson C, Nuss R, Jacobson L, et al. The varicella-autoantibody syndrome. Pediatr Res 2001; 50:345.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/21\" class=\"nounderline abstract_t\">Massano J, Ferreira D, Toledo T, et al. Stroke and multiple peripheral thrombotic events in an adult with varicella. Eur J Neurol 2008; 15:e90.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/22\" class=\"nounderline abstract_t\">Kurug&ouml;l Z, Vardar F, Ozkinay F, et al. Lupus anticoagulant and protein S deficiency in a child who developed disseminated intravascular coagulation in association with varicella. Turk J Pediatr 2001; 43:139.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/23\" class=\"nounderline abstract_t\">Regnault V, Boehlen F, Ozsahin H, et al. Anti-protein S antibodies following a varicella infection: detection, characterization and influence on thrombin generation. J Thromb Haemost 2005; 3:1243.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/24\" class=\"nounderline abstract_t\">Fukumoto S, Kinjo M, Hokamura K, Tanaka K. Subarachnoid hemorrhage and granulomatous angiitis of the basilar artery: demonstration of the varicella-zoster-virus in the basilar artery lesions. Stroke 1986; 17:1024.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/25\" class=\"nounderline abstract_t\">Constantinescu CS. Association of varicella-zoster virus with cervical artery dissection in 2 cases. Arch Neurol 2000; 57:427.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/26\" class=\"nounderline abstract_t\">Bhayani N, Ranade P, Clark NM, McGuinn M. Varicella-zoster virus and cerebral aneurysm: case report and review of the literature. Clin Infect Dis 2008; 47:e1.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/27\" class=\"nounderline abstract_t\">Askalan R, Laughlin S, Mayank S, et al. Chickenpox and stroke in childhood: a study of frequency and causation. Stroke 2001; 32:1257.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/28\" class=\"nounderline abstract_t\">Amlie-Lefond C, Bernard TJ, S&eacute;bire G, et al. Predictors of cerebral arteriopathy in children with arterial ischemic stroke: results of the International Pediatric Stroke Study. Circulation 2009; 119:1417.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/29\" class=\"nounderline abstract_t\">Braun KP, Bulder MM, Chabrier S, et al. The course and outcome of unilateral intracranial arteriopathy in 79 children with ischaemic stroke. Brain 2009; 132:544.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/30\" class=\"nounderline abstract_t\">Kang JH, Ho JD, Chen YH, Lin HC. Increased risk of stroke after a herpes zoster attack: a population-based follow-up study. Stroke 2009; 40:3443.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/31\" class=\"nounderline abstract_t\">Sreenivasan N, Basit S, Wohlfahrt J, et al. The short- and long-term risk of stroke after herpes zoster - a nationwide population-based cohort study. PLoS One 2013; 8:e69156.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/32\" class=\"nounderline abstract_t\">Breuer J, Pacou M, Gauthier A, Brown MM. Herpes zoster as a risk factor for stroke and TIA: a retrospective cohort study in the UK. Neurology 2014; 82:206.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/33\" class=\"nounderline abstract_t\">Langan SM, Minassian C, Smeeth L, Thomas SL. Risk of stroke following herpes zoster: a self-controlled case-series study. Clin Infect Dis 2014; 58:1497.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/34\" class=\"nounderline abstract_t\">Lin HC, Chien CW, Ho JD. Herpes zoster ophthalmicus and the risk of stroke: a population-based follow-up study. Neurology 2010; 74:792.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/35\" class=\"nounderline abstract_t\">Picard O, Brunereau L, Pelosse B, et al. Cerebral infarction associated with vasculitis due to varicella zoster virus in patients infected with the human immunodeficiency virus. Biomed Pharmacother 1997; 51:449.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/36\" class=\"nounderline abstract_t\">Berkefeld J, Enzensberger W, Lanfermann H. MRI in human immunodeficiency virus-associated cerebral vasculitis. Neuroradiology 2000; 42:526.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/37\" class=\"nounderline abstract_t\">Gray F, Mohr M, Rozenberg F, et al. Varicella-zoster virus encephalitis in acquired immunodeficiency syndrome: report of four cases. Neuropathol Appl Neurobiol 1992; 18:502.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/38\" class=\"nounderline abstract_t\">Petito CK, Cho ES, Lemann W, et al. Neuropathology of acquired immunodeficiency syndrome (AIDS): an autopsy review. J Neuropathol Exp Neurol 1986; 45:635.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/39\" class=\"nounderline abstract_t\">Ryder JW, Croen K, Kleinschmidt-DeMasters BK, et al. Progressive encephalitis three months after resolution of cutaneous zoster in a patient with AIDS. Ann Neurol 1986; 19:182.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/40\" class=\"nounderline abstract_t\">Nagel MA, Cohrs RJ, Mahalingam R, et al. The varicella zoster virus vasculopathies: clinical, CSF, imaging, and virologic features. Neurology 2008; 70:853.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/41\" class=\"nounderline abstract_t\">Hovens MM, Vaessen N, Sijpkens YW, de Fijter JW. Unusual presentation of central nervous system manifestations of Varicella zoster virus vasculopathy in renal transplant recipients. Transpl Infect Dis 2007; 9:237.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/42\" class=\"nounderline abstract_t\">Hall S, Carlin L, Roach ES, McLean WT Jr. Herpes zoster and central retinal artery occlusion. Ann Neurol 1983; 13:217.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/43\" class=\"nounderline abstract_t\">Gilden DH, Lipton HL, Wolf JS, et al. Two patients with unusual forms of varicella-zoster virus vasculopathy. N Engl J Med 2002; 347:1500.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/44\" class=\"nounderline abstract_t\">Persson A, Bergstr&ouml;m T, Lindh M, et al. Varicella-zoster virus CNS disease--viral load, clinical manifestations and sequels. J Clin Virol 2009; 46:249.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/45\" class=\"nounderline abstract_t\">Gregoire SM, van Pesch V, Goffette S, et al. Polymerase chain reaction analysis and oligoclonal antibody in the cerebrospinal fluid from 34 patients with varicella-zoster virus infection of the nervous system. J Neurol Neurosurg Psychiatry 2006; 77:938.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/46\" class=\"nounderline abstract_t\">Katchanov J, Siebert E, Klingebiel R, Endres M. Infectious vasculopathy of intracranial large- and medium-sized vessels in neurological intensive care unit: a clinico-radiological study. Neurocrit Care 2010; 12:369.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/47\" class=\"nounderline abstract_t\">Haug A, Mahalingam R, Cohrs RJ, et al. Recurrent polymorphonuclear pleocytosis with increased red blood cells caused by varicella zoster virus infection of the central nervous system: Case report and review of the literature. J Neurol Sci 2010; 292:85.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/48\" class=\"nounderline abstract_t\">Schubert J, Weissbrich B. Detection of virus-specific intrathecally synthesised immunoglobulin G with a fully automated enzyme immunoassay system. BMC Neurol 2007; 7:12.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/49\" class=\"nounderline abstract_t\">Nagel MA, Forghani B, Mahalingam R, et al. The value of detecting anti-VZV IgG antibody in CSF to diagnose VZV vasculopathy. Neurology 2007; 68:1069.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/50\" class=\"nounderline abstract_t\">Mathias M, Nagel MA, Khmeleva N, et al. VZV multifocal vasculopathy with ischemic optic neuropathy, acute retinal necrosis and temporal artery infection in the absence of zoster rash. J Neurol Sci 2013; 325:180.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/51\" class=\"nounderline abstract_t\">Teodoro T, Nagel MA, Geraldes R, et al. Biopsy-negative, varicella zoster virus (VZV)-positive giant cell arteritis, zoster, VZV encephalitis and ischemic optic neuropathy, all in one. J Neurol Sci 2014; 343:195.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/52\" class=\"nounderline abstract_t\">Nagel MA, Russman AN, Feit H, et al. VZV ischemic optic neuropathy and subclinical temporal artery infection without rash. Neurology 2013; 80:220.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/53\" class=\"nounderline abstract_t\">Salazar R, Russman AN, Nagel MA, et al. Varicella zoster virus ischemic optic neuropathy and subclinical temporal artery involvement. Arch Neurol 2011; 68:517.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/54\" class=\"nounderline abstract_t\">Nagel MA, Bennett JL, Khmeleva N, et al. Multifocal VZV vasculopathy with temporal artery infection mimics giant cell arteritis. Neurology 2013; 80:2017.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/55\" class=\"nounderline abstract_t\">Nagel MA, Khmeleva N, Boyer PJ, et al. Varicella zoster virus in the temporal artery of a patient with giant cell arteritis. J Neurol Sci 2013; 335:228.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/56\" class=\"nounderline abstract_t\">Gilden D, White T, Khmeleva N, et al. VZV in biopsy-positive and -negative giant cell arteritis: Analysis of 100+ temporal arteries. Neurol Neuroimmunol Neuroinflamm 2016; 3:e216.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/57\" class=\"nounderline abstract_t\">Breuer GS, Nesher R, Reinus K, Nesher G. Association between histological features in temporal artery biopsies and clinical features of patients with giant cell arteritis. Isr Med Assoc J 2013; 15:271.</a></li><li><a href=\"https://www.uptodate.com/contents/varicella-zoster-virus-vasculopathy/abstract/58\" class=\"nounderline abstract_t\">Gilden D, White T, Boyer PJ, et al. Varicella Zoster Virus Infection in Granulomatous Arteritis of the Aorta. J Infect Dis 2016; 213:1866.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 8271 Version 11.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H29\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2947884613\" id=\"outline-link-H2947884613\">VIROLOGY</a></li><li><a href=\"#H2730566247\" id=\"outline-link-H2730566247\">PATHOGENESIS OF VASCULOPATHY</a><ul><li><a href=\"#H464235702\" id=\"outline-link-H464235702\">Direct infection of blood vessels by VZV</a></li><li><a href=\"#H446592133\" id=\"outline-link-H446592133\">Role of autoantibodies</a></li></ul></li><li><a href=\"#H3396222153\" id=\"outline-link-H3396222153\">PATHOLOGY</a></li><li><a href=\"#H1702049186\" id=\"outline-link-H1702049186\">INTRACEREBRAL VZV VASCULOPATHY</a><ul><li><a href=\"#H8\" id=\"outline-link-H8\">Epidemiology</a><ul><li><a href=\"#H4074289790\" id=\"outline-link-H4074289790\">- Children</a></li><li><a href=\"#H117807219\" id=\"outline-link-H117807219\">- Adults</a></li></ul></li><li><a href=\"#H14\" id=\"outline-link-H14\">Clinical manifestations</a><ul><li><a href=\"#H15\" id=\"outline-link-H15\">- Neurologic manifestations</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">- Rash</a></li><li><a href=\"#H834882164\" id=\"outline-link-H834882164\">- Cerebrospinal fluid testing</a></li></ul></li><li><a href=\"#H464865366\" id=\"outline-link-H464865366\">Imaging</a><ul><li><a href=\"#H19\" id=\"outline-link-H19\">- Brain imaging</a></li><li><a href=\"#H20\" id=\"outline-link-H20\">- Angiographic features</a></li></ul></li><li><a href=\"#H22\" id=\"outline-link-H22\">Diagnosis</a><ul><li><a href=\"#H1367719343\" id=\"outline-link-H1367719343\">- When to suspect VZV</a></li><li><a href=\"#H23\" id=\"outline-link-H23\">- Laboratory testing</a></li></ul></li><li><a href=\"#H24\" id=\"outline-link-H24\">Differential diagnosis</a></li><li><a href=\"#H25\" id=\"outline-link-H25\">Treatment</a><ul><li><a href=\"#H3386040829\" id=\"outline-link-H3386040829\">- Initial regimen</a></li><li><a href=\"#H26\" id=\"outline-link-H26\">- Monitoring response to treatment</a></li><li><a href=\"#H2772046922\" id=\"outline-link-H2772046922\">- Patients who do not respond to initial treatment</a></li></ul></li></ul></li><li><a href=\"#H494763822\" id=\"outline-link-H494763822\">OTHER TYPES OF VASCULOPATHY</a><ul><li><a href=\"#H3647602221\" id=\"outline-link-H3647602221\">VZV vasculopathy with temporal artery infection</a></li><li><a href=\"#H3140366128\" id=\"outline-link-H3140366128\">VZV-associated granulomatous aortitis</a></li><li><a href=\"#H4159240775\" id=\"outline-link-H4159240775\">Management considerations</a></li></ul></li><li><a href=\"#H1911800653\" id=\"outline-link-H1911800653\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H29\" id=\"outline-link-H29\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/8271|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=ID/51689\" class=\"graphic graphic_diagnosticimage\">- MRI multifocal vasculop</a></li></ul></li><li><div id=\"ID/8271|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/74568\" class=\"graphic graphic_picture\">- Viral findings VZV vasc</a></li></ul></li><li><div id=\"ID/8271|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=RHEUM/54634\" class=\"graphic graphic_table\">- Features giant cell arteritis</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-of-varicella-zoster-virus-infection-chickenpox\" class=\"medical medical_review\">Clinical features of varicella-zoster virus infection: Chickenpox</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-of-giant-cell-temporal-arteritis\" class=\"medical medical_review\">Clinical manifestations of giant cell (temporal) arteritis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-of-varicella-zoster-virus-infection-herpes-zoster\" class=\"medical medical_review\">Clinical manifestations of varicella-zoster virus infection: Herpes zoster</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-and-pathogenesis-of-varicella-zoster-virus-infection-herpes-zoster\" class=\"medical medical_review\">Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-of-varicella-zoster-virus-infection-chickenpox\" class=\"medical medical_review\">Epidemiology of varicella-zoster virus infection: Chickenpox</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=extrapulmonary-manifestations-of-sarcoidosis\" class=\"medical medical_review\">Extrapulmonary manifestations of sarcoidosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=initial-assessment-and-management-of-acute-stroke\" class=\"medical medical_review\">Initial assessment and management of acute stroke</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=ischemic-stroke-in-children-and-young-adults-etiology-and-clinical-features\" class=\"medical medical_review\">Ischemic stroke in children and young adults: Etiology and clinical features</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=ischemic-stroke-in-children-evaluation-initial-management-and-prognosis\" class=\"medical medical_review\">Ischemic stroke in children: Evaluation, initial management, and prognosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neuroimaging-of-acute-ischemic-stroke\" class=\"medical medical_review\">Neuroimaging of acute ischemic stroke</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neurosyphilis\" class=\"medical medical_review\">Neurosyphilis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-and-approach-to-the-vasculitides-in-adults\" class=\"medical medical_review\">Overview of and approach to the vasculitides in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-evaluation-of-stroke\" class=\"medical medical_review\">Overview of the evaluation of stroke</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-management-of-vasculitis-in-adults\" class=\"medical medical_review\">Overview of the management of vasculitis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-of-giant-cell-arteritis\" class=\"medical medical_review\">Pathogenesis of giant cell arteritis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=primary-angiitis-of-the-central-nervous-system-in-adults\" class=\"medical medical_review\">Primary angiitis of the central nervous system in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-varicella-zoster-virus\" class=\"medical medical_society_guidelines\">Society guideline links: Varicella-zoster virus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-giant-cell-arteritis\" class=\"medical medical_review\">Treatment of giant cell arteritis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-varicella-chickenpox-infection\" class=\"medical medical_review\">Treatment of varicella (chickenpox) infection</a></li></ul></div></div>","javascript":null}